Clinical Progress in Treating Mitochondrial Disease MELAS Syndrome, Targeting the Root Cause with Gene Editing
Background
Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome is recognized as a representative rare disease with maternal inheritance. The core cause of the disease is attributed to mutations in mitochondrial DNA (mtDNA), the cell's energy source. Notably, approximately 80% of patients exhibit the m.3243A>G mutation, where the 3243th nucleotide in the mitochondrial genome is substituted from adenine to guanine. This mutation interferes with the normal metabolic process of transfer RNA (tRNA) responsible for transporting leucine, thereby blocking protein synthesis within the cell. As a result, functional loss gradually progresses, starting from energy-intensive tissues such as the brain and muscles, and eventually affecting the entire body. In current medical practice, there is a lack of fundamental treatments to halt disease progression, and management has relied solely on symptomatic therapies to address stroke-like episodes or lactic acidosis. Research aimed at interrupting the root pathological pathway and restoring mitochondrial function is urgently needed.
Key Findings
Clinical data and preclinical research results accumulated between 2024 and 2026 clearly demonstrate the potential for drug development to halt disease progression. First, high-dose taurine supplementation has emerged as a promising treatment. This therapy, approved by some regulatory agencies such as in Japan, involves administering 9–12 grams of taurine daily to patients. In phase 3 clinical trials, over 60% of patients showed preventive effects against recurrence of stroke-like episodes. It is interpreted that taurine directly compensates for the chemically modified tRNA deficient due to the mutation, thereby promoting mitochondrial protein synthesis.
Meanwhile, clinical trials of new drug candidates by global pharmaceutical companies are accelerating. Sonlicromanol, developed by Khondrion in the Netherlands, is classified as a targeted drug that controls the redox state and inflammation within cells. A phase 3 clinical trial targeting adult patients with the m.3243A>G mutation began in March 2026 and is ongoing. KL1333, developed by Abliva in Sweden, is in phase 2 clinical trials and works by regulating nicotinamide adenine dinucleotide (NAD+) levels to promote mitochondrial biosynthesis.
Improvements in cerebral vascular function are also being pursued. Zagociguat, an oral soluble guanylate cyclase (sGC) stimulator developed by Tisento Therapeutics, activates intracellular signaling pathways to dilate blood vessels and improve blood flow. A phase 2b clinical trial involving 43 adult patients has been completed, with major results expected in the fourth quarter of 2026.
In parallel, research into fundamental treatment through genome correction is gaining momentum. Precision gene-editing tools such as transcription activator-like effector nuclease (TALEN) and DddA-derived cytosine base editor (DdCBE) are being applied in research. These gene scissors have demonstrated therapeutic effects in restoring the ratio of mutant mtDNA to normal levels in cell line tests. Preclinical success has been achieved in reducing heteroplasmy levels to ensure that the proportion of mutant DNA does not exceed a certain threshold.
Significance and Outlook
These research achievements mark a paradigm shift in the medical community's approach to MELAS syndrome, moving from symptomatic treatment to causal correction. A new era of disease-modifying therapies that restore the metabolic capacity of cells themselves has begun. In particular, the clinical success of high-dose taurine therapy has set a milestone in the development of treatments for rare diseases by demonstrating its preventive effects against seizures. Small-molecule compounds in multi-center clinical trials also show high potential to become customized treatments for cognitive decline and chronic fatigue in patients.
However, there are still practical barriers to overcome before these treatments can be applied in clinical settings. For gene editing, it is essential to develop delivery technologies that can precisely deliver gene scissors to the target DNA within the mitochondria, which are deeply located in the cytoplasm. Challenges remain in minimizing off-target effects and ensuring genetic safety. Additionally, long-term safety must be further confirmed in multi-center clinical trials, and commercial journeys such as drug pricing registration and reimbursement benefits must be secured on a country-by-country basis.
Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome, most often caused by the m.3243A>G mitochondrial DNA variant, represents one of the most clinically significant inherited mitochondrial disorders. This variant disrupts mitochondrial tRNALeu(UUR) function, leading to impaired mitochondrial protein synthesis and progressive multisystem dysfunction. This narrative review synthesizes recent clinical trials, therapeutic advances, and emerging disease-modifying strategies for m.3243A>G-associated MELAS, with emphasis on evidence published between 2024 and 2026, drawing on PubMed/MEDLINE, Embase, the Cochrane Library, ClinicalTrials.gov, and the EU Clinical Trials Register. Key advances include:
The medical field and pharmaceutical industry can now establish concrete implementation plans based on these findings. Hospitals can introduce early genetic testing to identify infants and high-risk patients carrying the m.3243A>G mutation and establish a preventive treatment model by prescribing high-dose taurine before seizures begin. This can significantly reduce the rate of permanent brain damage caused by acute stroke-like episodes. In the field of new drug development, it is now possible to design combination therapy scenarios tailored to patient conditions based on clinical results of drugs with diverse mechanisms of action, such as sGC stimulators and NAD+ regulators. For example, patients at high risk of stroke can maintain vascular elasticity with zagociguat, while patients experiencing chronic fatigue and muscle weakness can be prescribed KL1333 in combination to simultaneously improve survival rates and daily functional capacity. Such treatment platforms aimed at activating mitochondrial function can also serve as a roadmap for developing therapies for other neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease, where mitochondrial dysfunction is implicated.